Table 2 Signal detection for thrombocytopenia associated with ICIs.

From: Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors

All regimens

Na

ROR

(95% one-sided Cl)b

PRR (χ2)c

BCPNN (IC025)d

MGPS

(EBGM05)e

Overall

404

7.86(7.11)

7.85(2266.66)

2.89

6.8

PD-1

306

8.1(7.23)

8.09(1806.52)

2.95

7.03

Nivolumab

174

7.94(6.83)

7.94(1024.1)

2.95

6.82

Pembrolizumab

128

7.98(6.7)

7.97(770.03)

2.97

6.76

Cemiplimab

3

5.24(1.69)

5.23(10.27)

2.39

2.03

PD-L1

63

6.69(5.22)

6.68(301.48)

2.73

5.38

Atezolizumab

37

5.91(4.3)

5.91(153.9)

2.55

4.5

Durvalumab

18

7.23(4.55)

7.22(96.18)

2.85

4.89

Avelumab

7

13.0(6.19)

12.98(77.32)

3.7

6.97

CTLA-4

37

6.42(4.65)

6.42(168.17)

2.67

4.87

Ipilimumab

37

6.42(4.65)

6.42(168.17)

2.67

4.87

Tremelimumab

0

0

0

0

0

  1. a: N, number of co-occurrences; b: ROR, reporting odds ratio (95% CI > 1, N ≥ 2); CI, confidence interval; c: PRR, proportional reporting ratio (PRR ≥ 2, χ2 ≥ 4, N ≥ 3); d: IC, information component; IC025, lower limit of the two-sided 95% CI of the IC; BCPNN, Bayesian confidence propagation neural network (IC025>0); e: EBGM, empirical Bayesian geometric mean; EBGM05, lower limit of the one-sided 95% CI of EBGM; MGPS, multi-item gamma Poisson shrinker (EBGM05>2, N>0).
Back to article page